Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gene therapy
6
×
glaxosmithkline
6
×
indiana blog main
6
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
6
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
novartis
abbvie
biogen
clinical trials
fda
gilead sciences
cancer immunotherapy
celgene
crispr
eli lilly
immunotherapy
What
bio
roundup
crispr
new
cancer
days
drug
news
pharma
remains
abbvie’s
acquisitions
ahead
albert
allogene
approval
august
biggest
biofourmis
biogen’s
biopharma
biopharmaceutical
biotech
bourla
bucks
busy
celebrate
ceo
chance
companies
company
congress
congressional
convo
corner
day
decisions
devices
diversity
drugs
Language
unset
unknown
Current search:
glaxosmithkline
×
photo
×
" indiana blog main "
×
" seattle blog main "
×
" gene therapy "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More